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ABSTRACT 
FMR1 premutation carriers (55-200 CGGs) are at risk of developing Fragile X-
associated primary ovarian insufficiency as well as Fragile X-associated tremor/ataxia 
syndrome. FMR1 premutation alleles are also associated with a variety of disorders, 
including psychiatric, developmental, and neurological problems. However, there is 
major concern regarding clinical implications of smaller CGG expansions known as 
intermediate alleles (IA) or gray zone alleles (45-54 CGG). Although several studies 
have hypothesized that IA may be involved in the etiology of FMR1 premutation 
associated phenotypes, this association still remains unclear. The aim of this study was 
to provide new data on the clinical implications of IA. We reviewed a total of 17,011 
individuals: 1,142 with primary ovarian insufficiency, 478 with movement disorders, 
14,006 with neurodevelopmental disorders and 1,385 controls. Similar IA frequencies 
were detected in all the cases and controls (cases 1.20% vs. controls 1.39%, p=0.427). 
When comparing the allelic frequencies of IA e50CGGs, a greater, albeit not 
statistically significant, number of alleles were detected in all the cohorts of patients. 
Therefore, IA below 50 CGGs should not be considered as risk factors for FMR1 
premutation associated phenotypes, at least in our population. However, the clinical 
implication of IA e  50CGGs remains to be further elucidated. 
 
Keywords: FMR1 intermediate alleles; grey zone; primary ovarian insufficiency; 
movement disorders; neurodevelopmental disorders; genetic counseling 
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INTRODUCTION 
The FMR1 gene is associated with significant morbidity. Since the description of the 
mutation responsible for fragile X syndrome (FXS) in 1991, we have made great 
progress in the knowledge of this gene and its broad spectrum of clinical implications. 
The CGG expansion in the FMR1 gene was the first disease described caused by a 
dynamic mutation. In the general population the repeat is between 6-44 CGG, while in 
FXS patients it is of more than 200 CGG which is considered as a full mutation (FM). 
This mutation generally leads to methylation of the repeat itself and the promoter region 
accompanied by silencing of the FMR1 gene. There are two more classes of alleles. The 
alleles between 55-200 CGG correspond to premutation alleles (PM) and are present in 
individuals who may develop different pathologies, the most relevant being Fragile X-
associated primary ovarian insufficiency (FXPOI) in females and a progressive 
neurodegenerative disorder called fragile X-associated tremor/ataxia syndrome 
(FXTAS) in both males and females (over 50-60 years). Lastly, there is another 
category of alleles called intermediate alleles (IA) or gray zone alleles. IA are between 
the normal and premutation ranges and are defined by the American College of 
Medical Genetics as having between 45 and 54 CGG repeats [1]. Despite population 
differences, according to a newborn screening in the United States the prevalence of IA 
is relatively high (1/66 females and 1/112 males) [2]. However, the clinical relevance 
of these IA alleles has been poorly studied. 
Although most IA are stable, some can occasionally expand to a PM in offspring and to 
a FM after two or three subsequent generations [3]. IA are more prone to expansion 
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when transmitted through males compared to females [4], and similar to PM the risk of 
expansion is affected by the AGG interruptions [5]. On the other hand, using highly 
sensitive quantification, Kenneson and collaborators [6] demonstrated significantly 
diminished FMRP levels, and a 1.5-fold increase of FMR1 mRNA which negatively 
correlated with the repeat number. 
While it is clear that the FM involves intellectual disability and autism and the PM 
involves a wide range of clinical manifestations with reduced penetrance, the clinical 
implications of IA remain unclear. Several studies have been carried out to determine 
whether these alleles have clinical repercussions or not. In relation to the frequency of 
IA in different disorders such as FXPOI, FXTAS, Parkinsonism, cognitive or behavioral 
disorders, there is controversy regarding whether the frequency is higher compared to 
the general population [7]. Therefore, further research is needed to fully elucidate the 
clinical significance of IA. The main objective of this study was to shed light on this 
issue in order to improve genetic counseling in these individuals. 
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MATERIAL AND METHODS 
Patients 
A retrospective review was performed of 15,626 cases recruited from four different 
genetic departments from around Spain (Table 1). All patients were referred for FMR1 
testing corresponding to unrelated individuals presenting a FMR1-associated disorder: 
1,142 females with primary ovarian insufficiency (POI), 478 (272 males and 206 
females) with movement disorders (MD) and 14,006 (12,319 males and 1,687 females) 
with neurodevelopmental disorders (NDD). Part of the NDD cohort was previously 
published in Madrigal and collaborators [8] (Table 1). All POI cases were unrelated 
cases referred by gynecological units for ovarian failure, infertility and/or early 
menopause. All the patients with MD were unrelated individuals referred by 
neurological units for unspecific spinocerebellar ataxia (SCA). Finally, patients with 
NDDs were referred by pediatricians, psychiatrists and neuropediatricians and included 
unrelated children with a broad spectrum of cognitive and behavioral phenotypes such 
as global developmental delay, attention deficit and hyperactivity, intellectual disability 
and autism spectrum disorders. 
All the patients or their parents provided written informed consent for testing and for 
the use of their phenotypic/clinical and genetic data. The study was approved by the 
Ethics Committee of the Hospital Clinic of Barcelona and was carried out in accordance 
with the Declaration of Helsinki (2013). 
Control population 
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The population based frequency of FMR1 alleles was obtained by screening of 1,385 
individuals (460 males and 925 females) recruited from the general population (Table 
1). Among these, we selected a subset cohort of 232 individuals above 40 years (135 
males and 97 females) in order to compare IA frequency from late-onset disorders. 
Molecular analysis 
DNA extraction from patients and controls was performed from peripheral blood using 
the Gentra Puregene blood kit (Qiagen) or a similar standard method. Molecular 
analysis of the FMR1 CGG repeat locus was performed in all laboratories of the 
participating centers following the same methods of PCR amplification using 
fluorescently labeled primers (upon request) and the GC-Rich PCR System (Sigma-
Aldrich) or the AmplideX PCR/CE FMR1 Kit (Asuragen). The results of the repeat 
number from all the laboratories were validated. 
Statistical analysis 
Statistical analyses were performed using commercially available software (SPSS-PC, 
version 23.0; SPSS Inc.). The chi-square test of frequencies and Fisher's exact test were 
applied to the contingency tables in order to compare IA frequencies between control 
and patient populations. Significance was accepted for exact asymptotic bilateral P-
values < 0.05. Bonferroni correction was performed for multiple comparisons. 
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RESULTS 
The allelic and genotypic frequencies of FMR1 IA alleles are summarized in Table 2. 
A total of 223 patients (29 with POI, 7 with SCA and 187 with NDD) and 32 controls 
from the general population were identified with IAs. Only one female with POI was 
found to be a carrier of two IA (50 and 53 CGGs).  
Similar IA frequencies were detected in all the cases and controls (cases 1.20% vs 
controls 1.39%, p=0.427). In order to adequately compare populations, the IA 
frequencies of the cohorts with POI and MD were compared with the entire control 
population and with a subset of the control population over 40 years of age. Regarding 
the NDD cohort, IA frequencies were compared to those detected in the whole control 
population. Statistical analysis did not show an excess of IA among any of the 
populations screened (Table 2). In fact, the frequency of IA carriers was significantly 
lower on comparing females with NDD and women in the control population (p=0.02), 
although this difference did not reach significance on applying the Bonferroni 
correction for multiple comparisons. 
On the other hand, a similar distribution was observed between IA harbored by cases 
and controls, being the most common allele (~25%) 45 CGGs in both groups (Figure 
1A). Moreover, using regression analysis we found a negative correlation between the 
CGG repeat size and the number of individuals carrying a specific allele (Figure 1B and 
1C). However, the coefficient of correlation was stronger in controls (R2 = 0.90) than in 
cases (R2 = 0.63). 
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Based on this observation, when comparing the allelic frequencies of IAe50 CGGs 
between cases and controls, we detected higher allelic frequencies in all the cohorts of 
patients (Table 3). However, statistical analysis did not identify significant differences 
neither in allelic or genotypic frequencies when comparing cases and controls. 
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DISCUSSION 
Taking into account the high frequency of IA in the general population, it is important 
to determine their possible effects on different disorders. The description of increased 
FMR1 mRNA levels in IA opened the debate regarding a possible clinical effect [9]. We 
performed a comparative analysis of the FMR1 CGG repeat locus in a large case-control 
study of several groups of individuals with FMR1 premutation associated pathologies. 
The frequency of IAs in the present study did not significantly differ from that obtained 
in the control population, suggesting the presence of an IA is not associated with the 
risk of POI, MD or NDD. 
In the last years, clinical and neuropsychological involvement has been associated with 
individuals carrying IA [9]. To date, 5 cases of FXTAS have been described in carriers 
of these alleles [10, 11]. In addition, an increased prevalence of IA has been reported in 
children with NDD [12-14] as well as in adults with POI or Parkinson’s disease (PD) 
[15-19]. Nevertheless, these findings do not agree with those of other authors [e.g. 8, 
20, 21]. However, it should be taken into account that the prevalence rates are difficult 
to compare across studies given the variable definitions of the IA CGG repeat range. 
In this study, 15,626 FMR1 alleles were screened among Caucasian patients diagnosed 
with MD, POI and NDD, being one of the largest reported up to now. Our results 
suggest that IA might not confer an increased risk of developing these disorders at least 
in Spanish populations. These results are consistent with a previous study by our group 
which included a subset of NDD patients [8]. 
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In the present study the age of the control population may be a limitation. In order to 
overcome this, we selected controls that were over 40 years of age to compare IA 
frequencies in late-onset disorders (POI and MD). Overall, we detected 2.31% of IA 
carriers among our Spanish control population including all males and females. This 
frequency did not significantly differ from that previously reported by Seltzer and 
collaborators [22] in 6,747 controls among males and females between 67-78 years in 
the United States. These authors reported a prevalence rate of 2.6% IA with the defined 
range of 45–54 repeats [22]. Therefore, our results could be compared with this latter 
study. 
In contrast with our results, some studies have reported an association between POI and 
IA [23]. However, they are not comparable with our data since the CGG repeat range 
used was different [15, 16]. In addition, other authors have described an increased 
frequency of IA in females with occult POI using the same 45-54 CGG repeat size as in 
our study [24]. Nevertheless, the association between IA and POI has not been 
replicated by several authors [20, 25, 26]. 
On the other hand, it has been reported an increased frequency of IA in patients with PD 
from different populations [17-19]. However, in agreement with our results a previous 
study by a Spanish group reported similar IA frequencies in 206 PD patients and 227 
control subjects [27]. 
In the last years, there have been more than 15 papers trying to elucidate the implication 
of IA in clinical disorders. Most support the fact that these alleles do not confer risk at 
least for the disorders associated to the FMR1 premutation, but we can not ignore the 
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reported cases such as patients with FXTAS or POI carrying IA and the molecular 
characteristics of IA which have a slight elevation of FMR1 mRNA and reduced FMRP 
levels, resembling what occurs in PM. If we accept a continuous transition from the 
normal to PM or FM status and taking into account the reduced penetrance in the FMR1 
premutation associated disorders, a model similar to the polygenic multifactorial 
inheritance could be considered. The IA could contribute to the development of the 
disease with less impact than PM alleles. In this model very few patients with IA would 
develop a disorder. This is in consonance with the results observed in the regression 
analysis of IA distribution. The present  study showed that in the group of patients there 
were more larger expanded alleles compared to the control population (Figure 1). In 
fact, when considering the range between 50 to 54 CGGs, we found higher IA 
frequencies among females with MD and in males with ID compared to sex-matched 
controls (Table 3). However, these differences were not statistically significant, 
although a higher number of controls with alleles within this range would be necessary 
to draw conclusions regarding this subgroup of carriers. Finally, other predisposing 
factors likely play an additional role in the development of the disease. 
In summary, our study provides one of the largest case control studies. Based on the 
screening of FMR1 CGG repeats in 15,626 patients, the results of this study do not 
support the implication of the IA in the appearance of MD, POI or NDD considering the 
current range of 45-55CGGs. According to these observations, IA below 50 CGGs 
should not be considered as risk factors for FMR1 premutation associated phenotypes, 
at least in our population. However, the clinical implication of IA e  50CGGs remains to 
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be further elucidated.Genetic counseling should undoubtedly be performed in all IA 
carriers  in order to assess the risk of expansion in the next generations.  
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Table 1. Individuals recruited for this study. 
 
POI 
MD NDD Controls 
B @ B @ B @ 
Hospital Clínic† 
(Barcelona) 
508 165 139 5,259 212 460 108 
Hospital Cruces‡ 
(Barakaldo-Bizkaia) 
337 77 15 2,496 492 - - 
Hospital La Fe§ 
(Valencia) 
239 26 50 4,053 744 - - 
Hospital Miguel Servet 
(Zaragoza) 
58 4 2 511 239 - - 
qGenomics Laboratory 
(Barcelona) 
- - - - - - 817 
TOTAL 1,142 272 206 12,319 1,687 460 925 
POI: primary ovarian insufficiency; MD: movement disorders; NDD: 
neurodevelopmental disorders; B: male individuals; @: female individuals 
†This cohort includes 4,753 male patients with intellectual disabilities and 275 male 
controls previously published [8]. 
‡This cohort includes 2,142 patients with intellectual disabilities (1,800 males and 342 
females) previously published [8]. 
§This cohort includes 1,550 male patients with intellectual disabilities previously 
published [8].  
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Table 2. Allelic and genotypic frequencies of FMR1 intermediate alleles (45-54 CGGs) 
in 1,142 females with primary ovarian insufficiency (POI), 478 patients with movement 
disorders (MD), 14,006 patients with neurodevelopmental disorders (NDD) and 1,385 
controls from the general population. Exact asymptotic bilateral P-values are shown. 
  Patients Control population 
  
POI MD NDD 
Whole 
cohort  
>40 years† 
(n=232) 
A
lle
lic
 f
re
qu
en
ci
es
 
IA (%) 
1.31% 
(30/2,284) 
1.02% 
(7/684) 
1.19% 
(187/15,693) 
1.39% 
(32/2,310) 
2.13% 
(7/329) 
p-value 
(rl whole cohort) 
P=0.90 P=0.57 P=0.48 - - 
p-value 
(rl older cohort) 
P=0.22 P=0.16 - - - 
G
en
ot
yp
ic
 f
re
qu
en
ci
es
 
Fe
m
al
es
 
IA (%) 
2.54% 
(29/1,142) 
2.91% 
(6/206) 
1.42% 
(24/1,687) 
2.70% 
(25/925) 
5.15%    
(5/97) 
p-value 
(rl whole cohort) 
P=0.89 P=0.82 P=0.02   
p-value 
(rl older cohort) 
P=0.18 P=0.34 -   
M
al
es
 
IA (%) NA 
0.37% 
(1/272) 
1.32% 
(163/12,319) 
1.52% 
(7/460) 
1.48% 
(2/135) 
p-value 
(rl whole cohort) 
- P=0.27 P=0.68   
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p-value 
(rl older cohort) 
- P=0.26 -   
† This cohort is a subset of the global control population recruited. rl: related to  
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Table 3. Allelic and genotypic frequencies of FMR1 intermediate alleles e50 CGGs in 
1,142 females with primary ovarian insufficiency (POI), 478 patients with movement 
disorders (MD), 14,006 patients with neurodevelopmental disorders (NDD) and 1,385 
controls individuals from the general population. Exact asymptotic bilateral P-values are 
shown 
  Patients Control 
population   POI MD NDD 
A
lle
lic
 
fr
eq
ue
nc
ie
s IA (%) 
0.35% 
(8/2,284) 
0.44% 
(3/684) 
0.50% 
(79/15,693) 
0.30% 
(7/2,310) 
p-value P=0.8 P=0.7 P=0.3 - 
G
en
ot
yp
ic
 f
re
qu
en
ci
es
 
Fe
m
al
es
 IA (%) 
0.61% 
(7/1,142) 
1.46% 
(3/206) 
0.30% 
(5/1,687) 
0.54% 
(5/925) 
p-value P=0.8 P=0.7 P=1  
M
al
es
 IA (%) NA 
0%   
(0/272) 
0.56% 
(69/12,319) 
0.43% 
(2/460) 
p-value - P=0.5 P=1  
  
This article is protected by copyright. All rights reserved.
  
FIGURE LEGENDS 
Fig. 1 Distribution of FMR1 intermediate alleles (45-54 CGGs). Black bars represent 
the cohort of patients (n=15,626) and grey bars represent the control population 
(n=1,385). (a) Percentage of cases and controls carriers of intermediate alleles; 
Regression analysis between the CGG repeat length (X-axis) and the number of cases 
(b) and controls (c) carriers of intermediate alleles (Y-axis) 
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